- Home
- CELH vs GH Comparison
CELH vs GH Comparison
Compare CELH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | GH |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 13.3B |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CELH | GH |
|---|---|---|
| Price | $41.44 | $87.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 20 |
| Target Price | $66.50 | ★ $117.80 |
| AVG Volume (30 Days) | ★ 5.4M | 1.7M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,318,014,000.00 | $982,021,000.00 |
| Revenue This Year | $35.89 | $33.40 |
| Revenue Next Year | $11.06 | $28.55 |
| P/E Ratio | $175.82 | ★ N/A |
| Revenue Growth | ★ 101.65 | 32.88 |
| 52 Week Low | $30.78 | $36.36 |
| 52 Week High | $66.74 | $120.74 |
Technical Indicators
Market Signals| Indicator | CELH | GH |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 36.20 |
| Support Level | $37.45 | $54.39 |
| Resistance Level | $47.24 | $103.16 |
| Average True Range (ATR) | 2.21 | 3.80 |
| MACD | -0.36 | -0.13 |
| Stochastic Oscillator | 0.95 | 34.57 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.